Niels J M Verstegen, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Jet van den Dijssel, Thomas Ashhurst, Laura Y L Kummer, Virginia Palomares Cabeza, Maurice Steenhuis, Mariël C Duurland, Rivka de Jongh, C Ellen van der Schoot, Veronique A L Konijn, Erik Mul, Katherine Kedzierska, Koos P J van Dam, Eileen W Stalman, Laura Boekel, Gertjan Wolbink, Sander W Tas, Joep Killestein, Theo Rispens, Luuk Wieske, Taco W Kuijpers, Filip Eftimov, Zoé L E van Kempen, S Marieke van Ham, Anja Ten Brinke, Carolien E van de Sandt
BACKGROUND: Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated with ocrelizumab (OCR), a B cell-depleting anti-CD20 monoclonal antibody, is not yet fully understood. METHODS: In this study, deep immune profiling techniques were employed to investigate the immune response induced by SARS-CoV-2 mRNA vaccines in untreated patients with MS (n=21), OCR-treated patients with MS (n=57) and healthy individuals (n=30)...
March 28, 2024: Journal of Neurology, Neurosurgery, and Psychiatry